A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: A Gynecologic Oncology Group study

L.M Landrum,W.E Brady,D.K Armstrong,K.N Moore,P.A Disilvestro,D.M O'Malley,M.E Tenney,P.G Rose,P.M Fracasso

doi:10.1016/j.ygyno.2015.01.053

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: A Gynecologic Oncology Group study

L.M Landrum, W.E Brady + Show 7 more

https://doi.org/10.1016/j.ygyno.2015.01.053

Copy DOI

Journal: Gynecologic Oncology	Publication Date: Apr 1, 2015
Citations: 1

Affiliation: University of Oklahoma, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, Johns Hopkins University, Brown University, The Ohio State University, Cleveland Clinic

#Pegylated Liposomal Doxorubicin #Fallopian Tube Cancer + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Objectives: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of two different regimens of ABT-888 when administered with carboplatin and PLD in recurrent platinum-sensitive epithelial ovarian, primary peritoneal, and fallopian tube cancer. A second component of the study was to examine the tolerability of these treatment regimens in combination with bevacizumab (10 mg/kg on days 1 and 15) at the MTD.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Gynecologic Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.